Alzamend Neuro Regains Nasdaq Compliance
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
Stocks · News reference
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascendiant Capital boosts Alzamend Neuro's target price, BTIG raises Henry Schein's target price, Cantor Fitzgerald increases Palo Alto's target price, Morgan Stanley cuts Baidu's target price, Cantor Fitzgerald slashes Crowdstrike Holdings' target price, Baird raises Donaldson Company's target price, B of A Securities cuts Pony AI's target price.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from
'Senators Move To Force AI Companies To Disclose More' - Semafor Exclusive
https://www.semafor.com/article/09/24/2026/senators-move-to-force-ai-companies-to-disclose-more
Shares of interactive media companies are trading lower as yields climb and investors anticipate future rate hikes amid inflation concerns. This may limit platforms from generating subscription and ad revenue as customers cut spending.
Baidu Reports Q2 2026 Results: Full Earnings Call Transcript
Baidu (NASDAQ:BIDU) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Is Baidu Inc. (BIDU) a Buy as Wall Street Analysts Look Optimistic?
While Baidu Inc. (BIDU) holds a Buy-equivalent average brokerage recommendation (ABR) of 1.75 from 21 analysts, the Zacks Rank system assigns it a Strong Sell rating due to a 19.3% decline in consensus earnings estimates over the past month. The article highlights the disconnect between potentially biased brokerage recommendations and the more reliable Zacks Rank, which is driven by earnings estimate revisions and has historically outperformed the S&P 500.